BHC
Undervalued by 6% based on the discounted cash flow analysis.
Market cap | $1.70 Billion |
---|---|
Enterprise Value | $562.23 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-0.13 |
Beta | 0.34 |
Outstanding Shares | 362,500,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -39.04 |
---|---|
PEG | 50.36 |
Price to Sales | 0.18 |
Price to Book Ratio | 0.06 |
Enterprise Value to Revenue | 0.06 |
Enterprise Value to EBIT | -0.43 |
Enterprise Value to Net Income | 1 |
Total Debt to Enterprise | 0 |
Debt to Equity | - |
No data
No data
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter ...